
## Ashly E Jordan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2120100/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and metaâ€analysis. Addiction, 2018, 113, 545-563.	3.3	242
2	Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. Aids, 2015, 29, 2335-2345.	2.2	197
3	Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. International Journal of Drug Policy, 2015, 26, 911-921.	3.3	88
4	Conceptualizing Care Continua: Lessons from HIV, Hepatitis C Virus, Tuberculosis and Implications for the Development of Improved Care and Prevention Continua. Frontiers in Public Health, 2016, 4, 296.	2.7	47
5	Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis. BMC Infectious Diseases, 2016, 16, 471.	2.9	43
6	Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006–2013. Drug and Alcohol Dependence, 2015, 152, 194-200.	3.2	42
7	Past-year prevalence of prescription opioid misuse among those 11 to 30 years of age in the United States: A systematic review and meta-analysis. Journal of Substance Abuse Treatment, 2017, 77, 31-37.	2.8	39
8	Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. , 2016, 2016, .		38
9	An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. International Journal of Drug Policy, 2015, 26, 1056-1063.	3.3	33
10	Big Events theory and measures may help explain emerging long-term effects of current crises. Global Public Health, 2021, 16, 1167-1186.	2.0	23
11	Acceptability and Effectiveness of Hepatitis C Care at Syringe Service Programs for People Who Inject Drugs in New York City. Substance Use and Misuse, 2021, 56, 728-737.	1.4	21
12	Prescription opioid misuse and its relation to injection drug use and hepatitis C virus infection: protocol for a systematic review and meta-analysis. Systematic Reviews, 2014, 3, 95.	5.3	16
13	Hepatitis C virus infection among HIV-positive men who have sex with men: protocol for a systematic review and meta-analysis. Systematic Reviews, 2014, 3, 31.	5.3	16
14	Patterns and Gaps Identified in a Systematic Review of the Hepatitis C Virus Care Continuum in Studies among People Who Use Drugs. Frontiers in Public Health, 2017, 5, 348.	2.7	12
15	Use of the PRECIS-II instrument to categorize reports along the efficacy-effectiveness spectrum in an hepatitis C virus care continuum systematic review and meta-analysis. Journal of Clinical Epidemiology, 2018, 93, 66-75.	5.0	10
16	Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City. Journal of Infectious Diseases, 2020, 222, S322-S334.	4.0	10
17	Perceptions of genetic testing and genomic medicine among drug users. International Journal of Drug Policy, 2015, 26, 100-106.	3.3	9
18	Combination interventions for Hepatitis C and Cirrhosis reduction among people who inject drugs: An agent-based, networked population simulation experiment. PLoS ONE, 2018, 13, e0206356.	2.5	8

Ashly E Jordan

#	Article	IF	CITATIONS
19	Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population. Clinical Infectious Diseases, 2020, 70, 2652-2662.	5.8	8
20	Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program. Journal of Infectious Diseases, 2020, 222, S335-S345.	4.0	8
21	The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis. Systematic Reviews, 2016, 5, 110.	5.3	7
22	Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation. Journal of Clinical Virology, 2020, 124, 104285.	3.1	6
23	Emerging Zoonotic Infections, Social Processes and Their Measurement and Enhanced Surveillance to Improve Zoonotic Epidemic Responses: A "Big Events―Perspective. International Journal of Environmental Research and Public Health, 2022, 19, 995.	2.6	5
24	Using qualitative data, people's perceptions, and the science of decision making to inform policy and improve hepatitis C care for people who use drugs. International Journal of Drug Policy, 2015, 26, 217-219.	3.3	4
25	Toward a Theory of the Underpinnings and Vulnerabilities of Structural Racism: Looking Upstream from Disease Inequities among People Who Use Drugs. International Journal of Environmental Research and Public Health, 2022, 19, 7453.	2.6	4
26	To neither target, capture, surveille, nor wage war: On-going need for attention to metaphor theory in care and prevention for people who use drugs. Journal of Addictive Diseases, 2017, 36, 1-4.	1.3	3
27	Hepatitis C Virus Disease Progression in People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis. JMIR Research Protocols, 2015, 4, e68.	1.0	3
28	Epidemiology of Hepatitis C Virus Among People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis. JMIR Research Protocols, 2017, 6, e201.	1.0	0